None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...